Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hydroxyurea (hydroxycarbamide) for sickle cell disease.

The Cochrane database of systematic reviews - 20 Apr 2017

Nevitt Sarah J, Jones Ashley P, Howard Jo

Abstract excerpt

BACKGROUND: Sickle cell disease (SCD) is one of the most common inherited diseases worldwide. It is associated with lifelong morbidity and a reduced life expectancy. Hydroxyurea (hydroxycarbamide), an oral chemotherapeutic drug, ameliorates some of the clinical problems of SCD, in particular that of pain, by raising fetal haemoglobin. This is an update of a previously published Cochrane Review. OBJECTIVES: To...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anemia, Sickle Cell
Share to Child
Share to Erythrocyte Transfusion

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to SCD gene

Share to Genotype

Share to Hydroxyurea

Share to Phlebotomy

Share to Randomized Controlled Trials as Topic

Source

Open in PubMed Open full text

Identifiers

PMID: 28426137
DOI: 10.1002/14651858.CD002202.pub2
PMCID: PMC6478259

Genes

SCD

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hydroxyurea (hydroxycarbamide) for sickle cell disease.PMID 28426137Read ↗

Effects of hydroxyurea treatment for patients with hemoglobin SC diseaseSemantic proximity Read ↗

Hydroxyurea for Children and Adults with Hemoglobin SC DiseaseSemantic proximity Read ↗

Hydroxyurea in the sickle cell disease modern eraSemantic proximity Read ↗

Drug Therapies for the Management of Sickle Cell DiseaseSemantic proximity Read ↗

Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent.Semantic proximity Read ↗

Current and emerging treatments for sickle cell diseaseSemantic proximity Read ↗

Optimizing hydroxyurea therapy for sickle cell anemia.Semantic proximity Read ↗

Chronic Administration of Hydroxyurea (HU) Benefits Caucasian Patients with Sickle-Beta Thalassemia.Semantic proximity Read ↗

A comprehensive review of hydroxyurea for β-haemoglobinopathies: the role revisited during COVID-19 pandemicSemantic proximity Read ↗

Hope on the Horizon: New and Future Therapies for Sickle Cell DiseaseSemantic proximity Read ↗

Evaluating the Therapeutic Effects of Amino Acid Treatment on Vaso-Occlusive Pain in Sickle Cell Disease: A Systematic Review and Meta-Analysis ProtocolSemantic proximity Read ↗

Hydroxyurea Treatment for Sickle Cell DiseaseSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.